Global trends in macrolide and lincosamide resistance in Streptococcus species: a comprehensive systematic review and meta-analysis
Abstract
BACKGROUND: The widespread use of macrolides and lincosamides, particularly for treating infections caused by Streptococcus pyogenes (S. pyogenes) (group A Streptococcus (GAS)), and S. pneumoniae has led to a concerning rise in antibiotic resistance. This meta-analysis aimed to evaluate the weighted pooled resistance rates of macrolides and lincosamides in clinical isolates of S. pneumoniae, S. pyogenes, and S. agalactiae (group B Streptococcus (GBS)) based on time, geographical areas, antimicrobial susceptibility testing, and guidelines. METHOD: We systematically searched PubMed, Embase, Web of Science, and Scopus for studies published between 2015 and 2023. Study quality was assessed via the Joanna Briggs Institute Checklist. Resistance rates were calculated with a random-effects model, supplemented by meta-regression, subgroup analyses, and identification of outliers. Statistical analyses were performed in R using the metafor package. RESULTS: This review analyzed 276 studies across 62 countries. Pooled resistance was highest for clarithromycin (57.6%) and azithromycin (55.8%), followed by erythromycin (41.5%) and clindamycin (29.5%), all with substantial heterogeneity (I2 > 98%, p < 0.001). Resistance differed significantly across various countries and continents (p < 0.001). Resistance patterns varied notably by species, with S. pneumoniae exhibiting the highest resistance to all tested macrolides and lincosamides, followed closely by S. agalactiae. In contrast, S.…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.